Clinical trials: Irritable Bowel Syndrome
Irritable Bowel Syndrome With Constipation (IBS-C)
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily…
- Trial name
- NCT05643534
- Testing
- Tenapanor 50 MG, Tenapanor 25 mg bid
- Where
- 39 sites in United States
- Volunteers
- 180 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome, Vaginal Health
A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health
This is a virtual single-group study that will last 12 weeks. Participants will take 1 capsule every day, with water. Questionnaires will be completed at baseline, 2 weeks, 4 weeks, and 12 weeks.
- Trial name
- NCT06124313
- Testing
- Vaginal Probiotic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rael
Irritable Bowel Syndrome
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00547469
- Testing
- DDP733
- Where
- 69 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Dynogen Pharmaceuticals
IBS - Irritable Bowel Syndrome
Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients
This is a Phase IV, open-label, single-center, proof-of-concept, pilot study to evaluate the effect of Lactibiane Tolerance® in treating leaky gut in IBS-D patients.
- Trial name
- NCT04898257
- Testing
- Multistrain probiotic
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Larena SAS
Irritable Bowel Syndrome, Digestive System Diseases
Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation…
- Conditions
- Irritable Bowel Syndrome, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases
- Trial name
- NCT01890837
- Testing
- Daikenchuto (TU-100)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Tsumura USA
Crohn Disease
Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
This study will evaluate the efficacy of capsule endoscopy (CE) versus ileocolonoscopy (IC) plus MRE for detection of active Crohn's disease (CD) in the small bowel in subjects with known CD and mucosal disease.
- Trial name
- BLINK (NCT03241368)
- Testing
- Capsule Endoscopy
- Where
- 26 sites in United States, Austria and 1 more
- Volunteers
- 187 people
- Sponsor
- Medtronic - MITG
Irritable Bowel Syndrome (IBS)
Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.
- Trial name
- NCT00316550
- Testing
- AV608
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Avera Pharmaceuticals
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Irritable Bowel Syndrome
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of…
- Trial name
- NCT03339128
- Testing
- Eluxadoline
- Where
- 46 sites in United States, Bulgaria and 7 more
- Volunteers
- 272 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS
Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome.
- Trial name
- NCT05348642
- Testing
- pasteurized A. muciniphila
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- A-Mansia Biotech S.A.
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome With Diarrhea
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome
Several probiotic strains have shown beneficial outcomes in IBS patients, particularly among the Lactobacillus and Bifidobacterium genera, Lactobacillus plantarum (recently reclassified as Lactiplantibacillus plantarum) is a…
- Trial name
- NCT04950296
- Testing
- Group I: L. plantarum UALp-05TM,, Group II: L. plantarum UALp-05TM,, Microcrystalline cellulose
- Where
- 12 sites in India
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Diarrhoea Predominant Irritable Bowel Syndrome
Retrospective Study of IBS-D Patients Previously Receiving SBI
This is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken EnteraGam for management of their IBS-D for at least eight weeks.
- Trial name
- NCT02661425
- Testing
- EnteraGam
- Where
- 16 sites in United States
- Volunteers
- 165 people
- Sponsor
- Entera Health, Inc
Irritable Bowel Syndrome With Diarrhea
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
- Trial name
- TARGET3 (NCT01543178)
- Testing
- open-label rifaximin, double-blind rifaximin
- Where
- 296 sites in United States, Germany and 1 more
- Volunteers
- 2,583 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Diarrhea
Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome
Randomized controlled clinical study has been proposed to evaluate the safety and efficacy of ES1 probiotic strain and heat-treated ES1 postbiotic strain in individuals suffering from IBS-D.
- Trial name
- NCT05339243
- Testing
- ES 1, HT ES1
- Where
- 8 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Irritable Bowel Syndrome With Constipation (IBS-C)
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.
- Trial name
- NCT05905926
- Testing
- Tenapanor
- Where
- 27 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome With Constipation, Chronic Constipation
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00730171
- Testing
- Linaclotide
- Where
- 116 sites in United States
- Volunteers
- 1,743 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Chronic Constipation, Irritable Bowel Syndrome With Constipation
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00765999
- Testing
- Linaclotide
- Where
- 118 sites in United States, Canada
- Volunteers
- 1,559 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC